Official ESCRS | European Society of Cataract & Refractive Surgeons
Vienna 2018 Delegate Registration Programme Exhibition Virtual Exhibition Satellites 2018 Survey


escrs app advert


Search Title by author or title

Postoperative opacification of a hydrophilic-hydrophobic acrylic intraocular lens: analysis of cases from 2010 to date

Poster Details

First Author: M.Alvarez SPAIN

Co Author(s):    A. Martinez-Abad   E. Rivera   F. Lugo Quinto   H. Albertos   V. Vargas   N. Subirana Pacheco   L. Bataille   J. Alio

Abstract Details


To study the prevalence and clinical characteristics of postoperative opacification of a hydrophilic-hydrophobic acrylic intraocular lens (IOL) as well as to analyse the clinical consequences


Vissum Corporation, Madrid and Alicante, Spain


Prospective observational study comprised by patients operated on different model of IOL Lentis Mplus (LS-312 MF30, LS-313 MF30 and LU-313 MF30T models) since 2010 until 2017. In all cases, a complete eye exam was performed evaluating the uncorrected and corrected distance visual acuity (VA) and the uncorrected and corrected near VA during the longest follow-up period. Opacification cases were registered and analyzed, comparing the data in the moment of the opacification diagnosis with the data in the medical discharge.


A total of 523 IOL Lentis Mplus were included, detecting 28 opacification cases (prevalence: 5.35%). Twenty seven of twenty eight opacification cases were manufactured before 06/2015 agreeing with the moment when the manufacturer (Oculentis GmbH) stop to use phosphate like a cleaning system. Mean time between the surgery and the opacification diagnosis was 53 months (range 13-86 months). The distribution according to the type of opacification was: 13 peripheral plaques, 6 central plaques and 9 diffused opacification. Nine of them affected visual axis, decreasing VA in 5 cases (VA mean decrease: 3.5 lines). Two cases required LIO explanted.


Opacification of the Lentis Mplus was found mainly in patients operated with IOLs manufactured before June 2015. Only 0.38% of cases required IOL explant by this reason.

Financial Disclosure:


Back to Poster listing